(RTTNews) - Pliant Therapeutics, Inc. (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin v8 and v1 inhibitor, in combination with pembrolizumab, in patients with immune checkpoint inhibitor -refractory advanced or metastatic solid tumors. The company said interim results demonstrated PLN-101095 anti-tumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily dose, representing a 50% objective response rate at the highest dose tested to date. Also, PLN-101095 was generally well tolerated across all doses.
PLN-101095 is an oral small molecule inhibitor of integrins v8 and v1. It is currently being evaluated in an ongoing first-in human Phase 1 dose-escalation trial. The Phase 1 trial is currently enrolling the fourth of five potential cohorts.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
